Bioremediation meets biomedicine: Therapeutic translation of microbial catabolism to the lysosome

Trends in Biotechnology

Volumn 20, Issue 11, 2002, Pages 452-455

  De Grey, Aubrey D N J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; BIOREMEDIATION; DEGRADATION; ENZYMES; MACROMOLECULES; MICROBIOLOGY;

LYSOSOMAL AGGREGATES;

BIOTECHNOLOGY;

AMINO ACID DERIVATIVE; BACTERIAL ENZYME; FUNGAL ENZYME; HYDROLASE;

BIOTECHNOLOGY;

AGING; ATHEROSCLEROSIS; BIOMEDICINE; BIOREMEDIATION; CATABOLISM; CELL AGGREGATION; CELL DAMAGE; CELL FUNCTION; CELL TYPE; DEGRADATION; ENZYME ACTIVITY; GENE THERAPY; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; MACROMOLECULE; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

AGING; BACTERIA; BIODEGRADATION, ENVIRONMENTAL; FUNGI; HUMANS; HYDROLASES; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; TRANSFORMATION, GENETIC;

BACTERIA (MICROORGANISMS);

EID: 0036843801     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(02)02062-0     Document Type: Review

References (40)

1. Bowers W.E. Christian de Duve and the discovery of lysosomes and peroxisomes. Trends Cell Biol. 8:1998;330-333.
2. Zhao H., Grabowski G.A. Gaucher disease: Perspectives on a prototype lysosomal disease. Cell. Mol. Life Sci. 59:2002;694-707.
3. Wisniewski K.E., et al. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology. 57:2001;576-581.
4. Schiffmann R., Brady R.O. New prospects for the treatment of lysosomal storage diseases. Drugs. 62:2002;733-742.
5. Hannover A. Mikroskopiske undersogelser af nervesystemet. Kongelige Danske Videnskabernes Selskabs. 10:1842;1-112.
6. Martin G.M. Genetic and evolutionary aspects of aging. Fed. Proc. 38:1979;1962-1967.
7. Terman A. Garbage catastrophe theory of aging: imperfect removal of oxidative damage? Redox Rep. 6:2001;15-26.
8. Lusis A.J. Atherosclerosis. Nature. 407:2000;233-241.
9. Roberts W.C., Shirani J. Comparison of cardiac findings at necropsy in octogenarians, nonagenarians, and centenarians. Am. J. Cardiol. 82:1998;627-631.
10. Broeckel U., et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nat. Genet. 30:2002;210-214.
11. Ikeda K., et al. Neurons containing Alz-50-immunoreactive granules around the cerebral infarction: evidence for the lysosomal degradation of altered tau in human brain? Neurosci. Lett. 284:2000;187-189.
12. Lim F., et al. TDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell. Neurosci. 18:2001;702-714.
13. Schenk D., et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 20:2001;679-681.
14. Brazil M.I., et al. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J. Biol. Chem. 275:2000;16941-16947.
15. Finnemann S.C., et al. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. Proc. Natl. Acad. Sci. U. S. A. 99:2002;3842-3847.
16. Davies S., et al. Photocytotoxicity of lipofuscin in human retinal pigment epithelial cells. Free Radic. Biol. Med. 31:2001;256-265.
17. Terman A., et al. Ceroid/lipofuscin-loaded human fibroblasts show decreased survival time and diminished autophagocytosis during amino acid starvation. Exp. Gerontol. 34:1999;943-957.
18. Brunk U.T., Terman A. The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autophagocytosis. Eur. J. Biochem. 269:2002;1996-2002.
19. Shamsi F.A., Boulton M. Inhibition of RPE lysosomal and antioxidant activity by the age pigment lipofuscin. Invest. Ophthalmol. Vis. Sci. 42:2001;3041-3046.
20. Nakano M., et al. Accumulation of cardiac lipofuscin in crab-eating monkeys (Macaca fasicularis): the same rate of lipofuscin accumulation in several species of primates. Mech. Ageing Dev. 66:1993;243-248.
21. de Grey A.D.N.J., Archer J.A.C. Why don't graveyards fluoresce? Anti-aging applications of the bacterial degradation of lysosomal aggregates. J. Am. Aging Assoc. 24:2001;118.
22. Snellinx Z., et al. Biological remediation of explosives and related nitroaromatic compounds. Environ. Sci. Pollut. Res. Int. 9:2002;48-61.
23. Pointing S.B. Feasibility of bioremediation by white-rot fungi. Appl. Microbiol. Biotechnol. 57:2001;20-33.
24. Nelson N., Harvey W.R. Vacuolar and plasma membrane proton-adenosinetriphosphatases. Physiol Rev. 79:1999;361-385.
25. Wang B., et al. Human cathepsin F. Molecular cloning, functional expression, tissue localization, and enzymatic characterization. J. Biol. Chem. 273:1998;32000-32008.
26. Woods N.B., et al. Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia. 16:2002;563-569.
27. Koransky M.L., et al. VEGF gene delivery for treatment of ischemic cardiovascular disease. Trends Cardiovasc. Med. 12:2002;108-114.
28. Shir A., Levitzki A. Gene therapy for glioblastoma: future perspective for delivery systems and molecular targets. Cell. Mol. Neurobiol. 21:2001;645-656.
29. Barranger J.M., Novelli E.A. Gene therapy for lysosomal storage disorders. Expert Opin. Biol. Ther. 1:2001;857-867.
30. Poenaru L. From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system. Ann. Med. 33:2001;28-36.
31. Brooks A.I., et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. U. S. A. 99:2002;6216-6221.
32. Le Borgne R., Hoflack B. Protein transport from the secretory to the endocytic pathway in mammalian cells. Biochim. Biophys. Acta. 1404:1998;195-209.
33. Cuervo A.M., Dice J.F. When lysosomes get old. Exp. Gerontol. 35:2000;119-131.
34. Kim J., Klionsky D.J. Autophagy, cytoplasm-to-vacuole targeting pathway, and pexophagy in yeast and mammalian cells. Annu. Rev. Biochem. 69:2000;303-342.
35. Shastri N., et al. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 20:2002;463-493.
36. Gura T. Hemophilia. After a setback, gene therapy progresses...gingerly. Science. 291:2001;1692-1697.
37. Zhang H.G., et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 16:1998;1045-1049.
38. Knosalla C., Cooper D.K. Xenotransplantation and tolerance. Front. Biosci. 7:2002;d1280-d1287.
39. Brix K., et al. Cysteine proteinases mediate extracellular prohormone processing in the thyroid. Biol. Chem. 382:2001;717-725.
40. Reddy A., et al. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell. 106:2001;157-169.